Scientists at the Imperial College London in England have been awarded nearly £100,000, or about $125,000, by Parkinson’s UK to identify new therapeutic targets for Parkinson’s disease. The grant was awarded to Michael Johnson, PhD, and his team, and will fund efforts to harness the power of computers…
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
The risk of developing Parkinson’s disease is double in adults older than 50 with anxiety relative to those without it in a recent U.K. study. Other Parkinson’s-associated symptoms, such as sleep issues, constipation, and tremors, were also associated with an elevated Parkinson’s risk in people with anxiety. “By understanding…
Kannalife Sciences has been awarded a $1.49 million grant from The Michael J. Fox Foundation (MJFF) to support the development of KLS-13019, the company’s novel cannabidiol- or CBD-derived therapy targeting neuroinflammation and mitochondrial dysfunction in Parkinson’s disease. KLS-13019 has shown promising results in preclinical models of…
The Aligning Science Across Parkinson’s (ASAP) initiative has launched a data-sharing platform that will make data on human brain samples available to researchers around the world, furthering research into Parkinson’s disease. The ASAP CRN Cloud includes several brain sequencing collections obtained from samples from four ASAP Collaborative…
The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first…
Synthetic biology company Bit.bio introduced ioAstrocytes, a stem cell-derived version of astrocytes, cells that are known to play a significant role in Parkinson’s disease. Dysfunction of the star-shaped cells in the central nervous system (CNS, consisting of the brain and spinal cord) has been linked to the development…
UB-312, a therapeutic vaccine candidate from Vaxxinity, safely led to antibodies being produced that could target toxic clumps of the alpha-synuclein protein in people with Parkinson’s disease, according to final published data from a Phase 1 clinical trial. Having detectable antibody levels against alpha-synuclein in the cerebrospinal fluid…
A Phase 2 clinical study of AB-1005 (AAV2-GDNF), an experimental gene therapy AskBio is developing for Parkinson’s disease, is recruiting patients who are experiencing motor fluctuations despite being on a stable medication regimen for at least a month. Called REGENERATE-PD (NCT06285643), the study aims to enroll 87…
The U.S. Food and Drug Administration (FDA) has rejected for the second time AbbVie’s application of ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults with advanced Parkinson’s disease. In a complete response letter to AbbVie, the FDA said the decision is based on observations from an inspection…
Get regular updates to your inbox.
